{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.3","value":"71.4"},{"groupId":"OG001","spread":"2.6","value":"76.9"},{"groupId":"OG002","spread":"2.8","value":"79.2"},{"groupId":"OG003","spread":"2.3","value":"85.9"}]}],"title":"EORTC QLQ30 global"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"90.3"},{"groupId":"OG001","spread":"2.3","value":"87.4"},{"groupId":"OG002","spread":"2.4","value":"90.3"},{"groupId":"OG003","spread":"1.8","value":"93.0"}]}],"title":"EORTC QLQ30 physical fcn"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.0","value":"81.9"},{"groupId":"OG001","spread":"3.4","value":"82.5"},{"groupId":"OG002","spread":"3.6","value":"85.6"},{"groupId":"OG003","spread":"2.2","value":"95.3"}]}],"title":"EORTC QLQ30 role fcn"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.8","value":"78.0"},{"groupId":"OG001","spread":"2.7","value":"87.7"},{"groupId":"OG002","spread":"3.7","value":"82.9"},{"groupId":"OG003","spread":"3.2","value":"88.2"}]}],"title":"EORTC QLQ30 emotional fcn"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"90.0"},{"groupId":"OG001","spread":"2.7","value":"89.5"},{"groupId":"OG002","spread":"3.1","value":"86.4"},{"groupId":"OG003","spread":"2.9","value":"90.7"}]}],"title":"EORTC QLQ30 cognitive fcn"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.4","value":"85.2"},{"groupId":"OG001","spread":"3.5","value":"85.1"},{"groupId":"OG002","spread":"3.7","value":"85.6"},{"groupId":"OG003","spread":"3.4","value":"90.3"}]}],"title":"EORTC QLQ30 social fcn"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.8","value":"14.4"},{"groupId":"OG001","spread":"4.1","value":"59.0"},{"groupId":"OG002","spread":"4.5","value":"47.7"},{"groupId":"OG003","spread":"4.2","value":"38.0"}]}],"title":"EORTC HN35 dry mouth"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.2","value":"15.7"},{"groupId":"OG001","spread":"4.4","value":"38.0"},{"groupId":"OG002","spread":"4.4","value":"27.3"},{"groupId":"OG003","spread":"4.6","value":"27.1"}]}],"title":"EORTC HN35 sticky saliva"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.8","value":"6.7"},{"groupId":"OG001","spread":"2.9","value":"25.7"},{"groupId":"OG002","spread":"3.3","value":"20.1"},{"groupId":"OG003","spread":"2.7","value":"15.9"}]}],"title":"EORTC HN35 senses"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.7","value":"24.4"},{"groupId":"OG001","spread":"2.7","value":"16.5"},{"groupId":"OG002","spread":"3.3","value":"14.2"},{"groupId":"OG003","spread":"2.3","value":"7.9"}]}],"title":"EORTC HN35 pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"18.4"},{"groupId":"OG001","spread":"2.6","value":"13.4"},{"groupId":"OG002","spread":"4.5","value":"19.2"},{"groupId":"OG003","spread":"2.6","value":"9.8"}]}],"title":"EORTC HN35 speech"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"81.3"},{"groupId":"OG001","spread":"2.0","value":"79.6"},{"groupId":"OG002","spread":"2.6","value":"76.9"},{"groupId":"OG003","spread":"2.3","value":"84.9"}]}],"title":"Composite MDADI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"43"}],"units":"Participants"}],"description":"Quality of life (QOL) patient-reported outcomes (PRO) for overall number of participants following treatment with elective volume and dose de-escalation, using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), EORTC HN35, which is specific to head and neck cancer, and composite MD Anderson Dysphagia Inventory (MDADI).\n\nEORTC QLQ-C30 and QLQ-H\\&N35 are scored on a 4-point categorical scale ranging from 1 \"not at all\" to 4 \"very much\". This scale is then linearly transformed to a 0-100 scale, where a higher score represents a higher response level. A high score for a functional scale represents higher level functioning, a high score for quality of life represents a high quality of life, and a high score for a symptom scale represents worse symptoms.\n\nMD Anderson Dysphagia Inventory (MDADI) questionnaire: Possible score ranges from 0-100, with higher score indicating higher functioning.","dispersionType":"Standard Error","groups":[{"description":"Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)\n\nIntensity Modulated Radiation Therapy: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.\n\nchemotherapy: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion","id":"OG000","title":"Total Cohort Baseline"},{"description":"Total cohort","id":"OG001","title":"Total Cohort 3 Month"},{"description":"Total cohort","id":"OG002","title":"Total Cohort 6 Month"},{"description":"Total cohort","id":"OG003","title":"Total Cohort 12 Month"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"12 months","title":"Quality of Life (QOL) Patient Reported Outcomes (PRO)","type":"SECONDARY","unitOfMeasure":"score on a scale"}